Our findings suggest that perturbations in the levels of GOT1/GOT2 within specific tissues reflect pathophysiological changes beyond tissue damage and have implications for cancer metabolism, immune infiltration, prognosis, and treatment personalization. This evidence concerns the gene GOT1 and cancer.